Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection

Treatment with a telaprevir-based regimen significantly improved sustained virologic response rates in patients with genotype 1 HCV, albeit with higher rates of discontinuation because of adverse events. (ClinicalTrials.gov number, NCT00336479.)